MMP9 AS MARKER OF ENDOMETRIAL CANCER

The present invention provides a method of diagnosis or prognosis endometrial carcinoma, the method comprising determining the level of expression of one or more proteins selected from the group consisting of: CLIC1, ANXA1, ANXA2, CAPG, CAYP1, CASP3, CD44, CADH1, XPO2, CTNB1, ENOA, FABP5, GSTP1, HSP...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	GIL MORENO, Antonio, MARTINEZ GARCÍA, Elena, REVENTÓS PUIGJANER, Jaume, DOMON, Bruno, LESUR, Antoine, COLÁS ORTEGA, Eva
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING PHYSICS TESTING
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention provides a method of diagnosis or prognosis endometrial carcinoma, the method comprising determining the level of expression of one or more proteins selected from the group consisting of: CLIC1, ANXA1, ANXA2, CAPG, CAYP1, CASP3, CD44, CADH1, XPO2, CTNB1, ENOA, FABP5, GSTP1, HSPB1, CH10, K2C8, NGAL, LDHA, MIF, MMP9, MUC1, NAMPT, PIGR, KPYM, PRDX1, SG2A1, GTR1, SPIT1, OSTP, TPIS and PDIA1, in an isolated fluid sample from the female genital tract..The present invention further provides kits for the diagnosis of the disease.